Reflexion Medical Raises $46 Million in Series B Financing

April 18, 2016 — RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy system for targeted, personalized cancer treatment, announced that it has closed a $46 million Series B round of funding. The financing was led by new investor KCK Group, a family investment fund. Also participating in the round were existing investors Pfizer Venture Investments, Venrock and Sofinnova Partners, RefleXion’s largest shareholder.

In conjunction with the financing, Nael Kassar and Greg Garfield from KCK Group will join the RefleXion board of directors. Current board members include Antoine Papiernik, Bill Burkoth, Colin Cahill, Fred Moll, M.D., Jay Watkins, Dr. Samuel Mazin and Akshay Nanduri.

Radiotherapy is a non-invasive cancer treatment procedure, often used in conjunction with medical and surgical oncology therapies. In the United States, approximately 1 million patients receive some form of radiotherapy every year. RefleXion’s biology-guided radiotherapy system (BgRT) utilizes both anatomic (computed tomography) and functional (positron emission tomography) imaging data to guide personalized radiotherapy. Delivering targeted treatment based on the patient’s individual biology, PET-CT guided radiotherapy has the potential to deliver a higher dose of therapeutic radiation to cancerous lesions while sparing surrounding healthy tissue.

“PET has been an effective tool to help diagnose and stage cancer using a radiotracer to map the higher metabolic activity of cancerous lesions. With this metabolic map, we could track multiple tumors in real time and precisely deliver targeted therapy based on that patient’s individual biology,” said Mazin, co-founder and president of RefleXion and inventor of the company’s core technology.

In addition to the potential of improving treatment efficacy for primary lesions and tracking of multiple tumors, the RefleXion biology-guided radiotherapy system may also enable several compelling applications of precision medicine. This may include the use of novel PET tracers to adapt treatment based on relevant biological tumor characteristics such as tumor hypoxia, cellular proliferation, DNA synthesis and genetic markers.

Proceeds from the Series B financing will be allocated towards expanding RefleXion’s engineering, regulatory and commercial organizations.

For more information: www.reflexionmedical.com